TEL AVIV, September 5, 2026, 7:45 p.m. IDT — Teva Pharmaceutical Industries (NYSE:TEVA; TASE:TEVA) now carries investment-grade ratings from all three major agencies. The milestone arrived without a rally. Its New York shares slipped 0.8% on Friday to $36.36.
The muted reaction makes sense. Teva’s outstanding notes already carry fixed coupons, so Friday’s upgrade cannot make those payments cheaper overnight.
The real benefit lies ahead. Better credit can widen the pool of bond buyers and improve future refinancing terms, just as $4.5 billion of debt has moved into current maturities.
S&P lifted Teva to BBB− from BB+ on Friday and assigned a stable outlook. Fitch reached BBB− in May. Moody’s followed with Baa3 in August.
Chief Financial Officer Eli Kalif said the final upgrade “further enhances our financial flexibility to invest in growth.” That is management’s case. The debt schedule shows where it must be proved.
The rating changed; the maturity test did not
Balance-sheet figures at June 30, 2026
This is not a forecast funding deficit. Teva also reported operating cash sources and a $1.8 billion revolving credit facility. Source: second-quarter Form 10-Q.
Teva held $3.655 billion in cash at June 30. It also reported a $1.8 billion revolving credit facility, alongside cash generated by the business.
Those resources mean the $845 million cash-to-maturity difference is not a funding forecast. It does, however, make refinancing terms consequential.
The timing matters. Every outstanding senior note bore a fixed interest rate at June 30. Existing coupons therefore do not reset merely because the rating improved.
Interest costs were already easing slowly. Net interest expense fell to $195 million in the second quarter from $203 million a year earlier. The six-month total declined to $396 million from $415 million.
S&P’s measure of adjusted leverage stood near 4 times after the second quarter. The agency expects mid-3-times leverage by year-end, then roughly 3.3 times in 2027. Sustained leverage above 4 times could bring another downgrade.
The final upgrade did not lift the stock
TEVA daily close, U.S. dollars; six sessions through Friday
Teva finished the six sessions from August 28 down 0.2%. Friday’s 7.4 million-share volume was almost twice Thursday’s level, but the stock closed lower.
Equity analysts are looking elsewhere for upside. UBS analyst Ashwani Verma raised his target to $48 from $42 and kept a Buy rating, citing progress in Teva’s celiac-disease pipeline. The new target sits 32% above Friday’s close.
Another capital-markets change arrives next week. The last day for Teva’s American depositary shares is September 11. Ordinary shares begin direct NYSE trading on September 14, with no proceeds going to the company.
The risks remain operational as well as financial. Pipeline setbacks, generic-drug pricing, litigation and Middle East disruption could slow deleveraging. A softer earnings path would also weaken the refinancing benefit that investment grade now offers.
Teva has crossed the ratings threshold. Shareholders now need the cheaper funding to show up in future deals—and the product pipeline to protect the cash behind them.
